Merck & Co., Inc. Impairment of Intangible Assets, Finite-lived
Merck & Co., Inc. (MRK) reported Impairment of Intangible Assets, Finite-lived of $705.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2022-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2022-02-25
- Merck & Co., Inc. impairment of intangible assets, finite-lived for the quarter ending 2019-12-31 was $12.00M.
- Merck & Co., Inc. impairment of intangible assets, finite-lived for the quarter ending 2019-09-30 was $612.00M.
- Merck & Co., Inc. impairment of intangible assets, finite-lived for the quarter ending 2016-12-31 was $0.00.
- Merck & Co., Inc. impairment of intangible assets, finite-lived for the quarter ending 2016-09-30 was $0.00.
- Merck & Co., Inc. impairment of intangible assets, finite-lived for fiscal 2019 was $705.00M.
- Merck & Co., Inc. impairment of intangible assets, finite-lived for fiscal 2017 was $58.00M, a 83.29% decline from fiscal 2016.
- Merck & Co., Inc. impairment of intangible assets, finite-lived for fiscal 2016 was $347.00M, a 671.11% increase from fiscal 2015.
- Merck & Co., Inc. impairment of intangible assets, finite-lived for fiscal 2015 was $45.00M, a 95.91% decline from fiscal 2014.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2019-12-31 | $12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $624.00M derived: sum of 2 quarters · filed 2022-02-25 | $705.00M 10-K · filed 2022-02-25 | |
| 2019-09-30 | $612.00M 10-Q · filed 2020-11-05 | $693.00M 10-Q · filed 2020-11-05 | ||
| 2017-12-31 | $58.00M 10-K · filed 2020-02-26 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $0.00 derived: sum of 2 quarters · filed 2019-02-27 | $95.00M derived: sum of 3 quarters · filed 2019-02-27 | $347.00M 10-K · filed 2019-02-27 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $95.00M derived: sum of 2 quarters · filed 2017-11-07 | $347.00M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $95.00M 10-Q · filed 2017-08-08 | $347.00M 10-Q · filed 2017-08-08 | ||
| 2015-12-31 | $45.00M 10-K · filed 2018-02-27 | |||
| 2015-03-31 | $12.00M 10-Q · filed 2015-05-07 | $12.00M derived: sum of 2 quarters · filed 2017-02-28 | $424.00M derived: sum of 3 quarters · filed 2017-02-28 | $1.08B derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $412.00M derived: sum of 2 quarters · filed 2017-02-28 | $1.07B derived: sum of 3 quarters · filed 2017-02-28 | $1.10B 10-K · filed 2017-02-28 |
| 2014-09-30 | $412.00M 10-Q · filed 2015-11-05 | $1.07B derived: sum of 2 quarters · filed 2015-11-05 | $1.10B 10-Q · filed 2015-11-05 | |
| 2014-06-30 | $660.00M 10-Q · filed 2015-08-06 | $660.00M 10-Q · filed 2015-08-06 | ||
| 2013-12-31 | $486.00M 10-K · filed 2016-02-26 | |||
| 2013-09-30 | $330.00M 10-Q · filed 2013-08-07 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $0.00 derived: sum of 2 quarters · filed 2014-02-27 | $118.00M derived: sum of 3 quarters · filed 2014-02-27 | $118.00M 10-K · filed 2014-02-27 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $118.00M derived: sum of 2 quarters · filed 2012-11-09 | $118.00M 10-Q · filed 2012-11-09 | |
| 2011-06-30 | $118.00M 10-Q · filed 2012-08-07 | $118.00M 10-Q · filed 2012-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |